2026-04-13T02:17:43Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/130782025-10-24T08:24:43Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
COLLAZO LORDUY, ANA
author
Azkona-Uribelarrea, Eider
author
Guillen-Sentís, Pau
author
APARISI APARISI, FRANCISCO DE ASIS
author
Ospina, Vanessa
author
Lopez Castro, Rafael
author
Valdivia Bustamante, Augusto
2025-10-24T08:24:43Z
2025-10-24T08:24:43Z
2025-05-14T06:21:00Z2025-05-14T06:21:00Z2025-04
http://hdl.handle.net/11351/13078
Lung cancer; Oncological treatment; Sexual dysfunctionCáncer de pulmón; Tratamiento oncológico; Disfunción sexualCàncer de pulmó; Tractament oncològic; Disfunció sexualBackground
Patients with lung cancer may suffer from sexual dysfunction (SD) related to oncological treatment. This is an under-recognized condition among clinicians. The aim of this study was to describe the prevalence of SD in a multicenter cohort of patients.
Patients and methods
This multicenter, cross-sectional, observational study was conducted between July 2023 and February 2024. Sexual function was assessed by patient-reported outcome (PRO) system using sex-specific questionnaire. Descriptive analysis and evaluation of differences between categorical variables were carried out. Associations between clinical characteristics and SD were assessed by logistic regression.
Results
Four hundred and forty-eight patients from 24 hospitals in Spain, Colombia, Argentina, and Portugal were included. Of these, 277 (61.83%) were male and 365 (81.48%) had metastatic disease. Two hundred and eighty-four patients (63.39%) reported the onset of SD following the initiation of oncological treatment. Males and females reported a high frequency of severe impairment of sexual response phases, which was twice as high in females (P = 0.001). Female sex was a factor for severe impairment of desire, arousal, and orgasm [odds ratio (OR) 3.72, 95% confidence interval (CI) 2.48-5.60, P = 0.001] and decreased sexual activity (OR 1.98, 95% CI:1.17-3.19, P = 0.01), in addition to age over 65 years (OR 3.86, 95% CI 1.01-15.25, P = 0.004) and high educational level (OR 0.29, 95% CI 0.09-0.94, P = 0.0040). Patients from Portugal and Latin America were more likely to report dissatisfaction with sexual activity (OR 3.75, 95% CI 1.06-13.22, P = 0.0039). Female sex (OR 3.53, 95% CI 1.88-6.6, P 0.001), smoking history (OR 1.77, 95% CI 1.01-4.01, P = 0.04), and obesity (OR 1.70 95% CI 1.01-3.16, P = 0.05) were associated with global sexual dissatisfaction.
Conclusions
Our patients with lung cancer had a high prevalence of SD after initiation of oncological treatment. There was remarkable sex disparity in the frequency and severity of this disorder as well as an important influence of sociocultural factors in the clinical presentation.This academic research was developed by the Spanish Lung Cancer Group/Grupo Español de Cancer de Pulmón GECP (no grant number).
Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess
Qüestionaris
Pulmons - Càncer
Trastorns sexuals
Medicaments antineoplàstics - Ús terapèutic - Efectes secundaris
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence
DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms
DISEASES::Male Urogenital Diseases::Genital Diseases, Male::Sexual Dysfunction, Physiological
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
Other subheadings::Other subheadings::Other subheadings::/adverse effects
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::estadísticas vitales::morbilidad::prevalencia
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares
ENFERMEDADES::enfermedades urogenitales masculinas::enfermedades de los genitales masculinos::disfunción sexual fisiológica
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
LUDICAS: sexual dysfunction in patients with lung cancer, a multicenter cross-sectional study
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion